China's pharmaceuticals market is forecast to become the world's fifth largest by 2010. Multinational companies with early investments made in China have put China on the global map with the worldwide planning of a global new product introduction which includes the China market. New product entries in the China market face a range of very complex obstacles, including the resolve of issues such as regulatory affaire requirements for free sales in the market, distribution access to hospitals / retail pharmacies, intellectual property rights, listing / reimbursement and price control. LFE has the expertise to provide the client with the definition of an entry strategy in China.

With its expertise of regulatory affair service, marketing research and clinical trial service, LFE is able to provide market entry strategy consulting service in the following fields.

Regulatory requirements for market entry

relevant government institutions and procedure

regulatory administration of various products: medicine, 

medical device and equipment, medical nutrition, functional

food ingredients, reagents, hygienic products, etc.

requirements of dossier / documents for IND, NDA, IPL

(import product license) and MP (manufacturing permit)

requirement of specification validation and sample testing

time line and plan of action

pre-consulting meeting with relevant government bureau

Market assessment

market size

competitive profile: key competitors and their activities

price strategy: price ranges of key products, price chain,

pricing scenarios

customers' AAU: (awareness, attitudes and usage)

P & L estimation of operation in first 5 years: costs of market

entry, operation and inputs from clients

Loudon China provides market entry consulting service for various life science industry,

Pharmaceutical products

Medical equipments and devices

Healthcare service

Medical nutrition products